1Juvan-Vague I,Alessi MC.Plasminogen activator inhibitor-1 and atherorombosis.Thromb Haemost,1993,70:138-143.
2Visanji JM,Seargent J,Tahri D,et al.Influence of the -675 4G/5Gdimorphism of the plasminogen activator inhibitor promoter on thrombotic risk in patients with factor V Leiden.Br J Haematol,2000,110:135-138.
3Glueck CJ,Phillips H,Cameron D,et al. The 4G/5G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene:an independent risk factor for serious pregnancy complications.Metabolism, 2000,49:845-852.
4Iwai N,Shimoike H,Nakamura Y,et al.The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes.Atherosclerosis,1998 , 136 : 109-114.
8Wilson WA,Gharavi AE,Koike T,et al.International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome:report of an international workshop[J].Arthritis Rheum,1999,42(7):1309-1311.
9McNeil HP,Simpson RJ,Chesterman CN,et al.Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation:beta 2-glycoprotein I(apolipoprotein H)[J].Proc Natl Acad Sci USA,1990,87(11):4120-4124.
10Pierangeli SS,Gharalvi AE,Harris EN.Testing for antiphospholipid antibodies:problems and solutions[J].Clin Obstet Gynecol,2001,44(1):48-57;quiz 58-59.
